Compare Albertsons Companies Inc (ACI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Gilead Sciences, Inc. — how do they compare? Albertsons Companies Inc trades at $12.35 (market cap $5.95B), while Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 28.3× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ACI | GILD | |
|---|---|---|
Market Cap | $5.95B | $168.35B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $155.80 |
52-Week Low | $11.03 | $110.56 |
Enterprise Value | $21.35B | $191.42B |
Dividend Yield | 5.55% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
